Adverum Biotechnologies, Inc. (ADVM)
NASDAQ
Market Cap
$144.88M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
197 of 809
Rank in Industry
123 of 445
Largest Insider Buys in Sector
ADVM Stock Price History Chart
ADVM Stock Performance
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Activity of Adverum Biotechnologies, Inc.
Over the last 12 months, insiders at Adverum Biotechnologies, Inc. have bought $310,500 and sold $9,429 worth of Adverum Biotechnologies, Inc. stock.
On average, over the past 5 years, insiders at Adverum Biotechnologies, Inc. have bought $322,261 and sold $836,807 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lupher, Jr. Mark L. (director) — $175,500. Scopa James Paul (director) — $135,000.
The last purchase of 130,000 shares for transaction amount of $175,500 was made by Lupher, Jr. Mark L. (director) on 2024‑02‑07.
List of Insider Buy and Sell Transactions, Adverum Biotechnologies, Inc.
| 2024-02-07 | Lupher, Jr. Mark L. | director | 130,000 0.1654% | $1.35 | $175,500 | -59.61% | ||
| 2024-02-07 | Scopa James Paul | director | 100,000 0.1273% | $1.35 | $135,000 | -59.61% | ||
| 2023-09-15 | Sale | Seyedkazemi Setareh | Chief Development Officer | 6,201 0.006% | $1.52 | $9,429 | -38.75% | |
| 2023-06-07 | Rubinstein Linda M | Chief Financial Officer | 100,000 0.098% | $1.45 | $145,490 | -18.95% | ||
| 2023-03-15 | Sale | Fischer Laurent | CEO, President and Director | 41,239 0.0397% | $0.78 | $32,232 | +25.15% | |
| 2023-03-15 | Sale | Soparkar Peter | Chief Operating Officer | 13,360 0.0128% | $0.78 | $10,442 | +25.15% | |
| 2023-03-15 | Sale | Riley Brigit | Chief Scientific Officer | 7,299 0.007% | $0.78 | $5,705 | +25.15% | |
| 2022-05-23 | Seyedkazemi Setareh | Chief Development Officer | 20,000 0.0205% | $0.84 | $16,800 | +0.48% | ||
| 2022-05-17 | Beckman Richard | Chief Medical Officer | 10,000 0.01% | $0.82 | $8,228 | +0.60% | ||
| 2022-05-16 | Svoronos Dawn | 30,000 0.0319% | $0.85 | $25,578 | +2.84% | |||
| 2022-05-13 | D'Souza Rupert | Chief Financial Officer | 10,000 0.0104% | $0.86 | $8,585 | +0.06% | ||
| 2022-04-20 | Fischer Laurent | CEO, President and Director | 25,000 0.0246% | $1.11 | $27,800 | -23.16% | ||
| 2022-04-19 | Soparkar Peter | See Remarks section | 21,750 0.0224% | $1.14 | $24,795 | -21.79% | ||
| 2021-12-09 | Fischer Laurent | CEO, President and Director | 14,323 0.0147% | $1.85 | $26,498 | -35.87% | ||
| 2021-12-08 | Fischer Laurent | CEO, President and Director | 10,677 0.0104% | $1.79 | $19,112 | -36.90% | ||
| 2021-12-08 | Soparkar Peter | See Remarks section | 25,000 0.026% | $1.91 | $47,750 | -36.90% | ||
| 2021-11-15 | Sale | Scopa James Paul | director | 50,000 0.0512% | $2.18 | $109,000 | -41.71% | |
| 2021-09-30 | Sale | Clark Julie | Chief Medical Officer | 4,766 0.0049% | $2.17 | $10,342 | -35.94% | |
| 2021-03-31 | Svoronos Dawn | director | 20,000 0.0207% | $10.02 | $200,338 | -77.38% | ||
| 2021-03-24 | Machado Patrick | director | 10,000 0.011% | $9.92 | $99,196 | -75.69% |
Insider Historical Profitability
<0.0001%
| Lupher, Jr. Mark L. | director | 130000 0.1287% | $6.98 | 1 | 0 | |
| Scopa James Paul | director | 100000 0.099% | $6.98 | 3 | 1 | +22.77% |
| Seyedkazemi Setareh | Chief Development Officer | 47674 0.0472% | $6.98 | 1 | 1 | +0.48% |
| Zygtech, LLC | 10 percent owner | 2438176 2.4134% | $6.98 | 0 | 3 | |
| Venrock Associates VI, L.P. | 10 percent owner | 2365471 2.3414% | $6.98 | 1 | 0 | |
| Venrock Healthcare Capital Partners II, L.P. | 10 percent owner | 2365471 2.3414% | $6.98 | 1 | 0 | |
| REGENERON PHARMACEUTICALS INC | 10 percent owner | 1809098 1.7907% | $6.98 | 1 | 0 | |
| Fischer Laurent | CEO, President and Director | 692141 0.6851% | $6.98 | 6 | 1 | <0.0001% |
| Flynn James E | 10 percent owner | 654285 0.6476% | $6.98 | 1 | 0 | |
| Blumenkranz Mark S. | director | 522989 0.5177% | $6.98 | 0 | 13 | |
| Schwartz Steven Daniel | director | 367931 0.3642% | $6.98 | 0 | 7 | |
| Gasmi Mehdi | director | 274442 0.2717% | $6.98 | 0 | 22 | |
| Soparkar Peter | Chief Operating Officer | 265891 0.2632% | $6.98 | 3 | 1 | <0.0001% |
| Chalberg Thomas W. | Chief Executive Officer | 258988 0.2564% | $6.98 | 0 | 3 | |
| Clark Julie | Chief Medical Officer | 164723 0.163% | $6.98 | 0 | 1 | |
| Riley Brigit | Chief Scientific Officer | 117435 0.1162% | $6.98 | 0 | 1 | |
| Rubinstein Linda M | Chief Financial Officer | 100000 0.099% | $6.98 | 1 | 0 | <0.0001% |
| PATTERSON LEONE D | President and CFO | 97955 0.097% | $6.98 | 0 | 6 | |
| Machado Patrick | director | 88182 0.0873% | $6.98 | 2 | 0 | |
| Svoronos Dawn | 50000 0.0495% | $6.98 | 2 | 0 | +2.84% | |
| Wachter Paul | director | 37161 0.0368% | $6.98 | 0 | 11 | |
| Hull Hans | SVP, Business Operations | 11320 0.0112% | $6.98 | 0 | 3 | |
| D'Souza Rupert | Chief Financial Officer | 10850 0.0107% | $6.98 | 1 | 0 | +0.06% |
| Beckman Richard | Chief Medical Officer | 10000 0.0099% | $6.98 | 1 | 0 | +0.6% |
| Bain Linda | Chief Financial Officer | 9000 0.0089% | $6.98 | 0 | 4 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Tcg Crossover Management Llc | $28.4M | 9.68 | 2.01M | New | +$28.4M | 0.05 | |
| Vr Adviser Llc | $22.01M | 7.5 | 1.56M | -69.76% | -$50.78M | 1.07 | |
| Vivo Capital | $21.21M | 7.23 | 1.5M | New | +$21.21M | 1.87 | |
| Logos Global Management Lp | $21.21M | 7.23 | 1.5M | New | +$21.21M | 2.28 | |
| Frazier Life Sciences Management L P | $15.12M | 5.15 | 1.07M | New | +$15.12M | 0.78 | |
| The Vanguard Group | $12.83M | 4.37 | 907,151 | -78.34% | -$46.41M | <0.0001 | |
| Fidelity Investments | $12.73M | 4.34 | 900,527 | -85.3% | -$73.86M | <0.01 | |
| Bml Capital Management Llc | $11.78M | 4.01 | 833,117 | -81.71% | -$52.62M | 8.97 | |
| Franklin Templeton Investments | $9.55M | 3.26 | 675,675 | New | +$9.55M | <0.01 | |
| Commodore Capital, LP | $9.29M | 3.17 | 657,333 | -93.43% | -$132.11M | 0.66 | |
| Morgan Stanley | $7.95M | 2.71 | 562,035 | -89.09% | -$64.88M | <0.01 | |
| 5Am Venture Management Llc | $7.66M | 2.61 | 541,666 | New | +$7.66M | 0.52 | |
| Versant Ventures | $7.17M | 2.44 | 506,822 | -90% | -$64.5M | 9.99 | |
| Laurion Capital Management LP | $6.21M | 2.12 | 438,935 | New | +$6.21M | 0.17 | |
| Avoro Capital Advisors Llc | $5.89M | 2.01 | 416,666 | New | +$5.89M | 0.07 | |
| Assenagon Asset Management S.A. | $5.07M | 1.73 | 358,719 | New | +$5.07M | 0.01 | |
| BlackRock | $4.47M | 1.53 | 316,450 | -77.42% | -$15.34M | <0.0001 | |
| Samsara Biocapital Llc | $4.12M | 1.41 | 291,666 | New | +$4.12M | 0.64 | |
| Millennium Management LLC | $3.52M | 1.2 | 248,642 | -16.55% | -$697,031.32 | <0.01 | |
| Geode Capital Management | $2.74M | 0.93 | 193,516 | -77.61% | -$9.49M | <0.0001 | |
| Bank of America | $2.34M | 0.8 | 165,495 | -96.15% | -$58.46M | <0.0001 | |
| Aigh Capital Management Llc | $2.3M | 0.78 | 162,547 | -94.88% | -$42.57M | 1.36 | |
| Marshall Wace | $1.89M | 0.65 | 133,851 | New | +$1.89M | <0.01 | |
| Renaissance Technologies | $1.88M | 0.64 | 133,088 | -92.91% | -$24.67M | <0.01 | |
| Picton Mahoney Asset Management | $1.75M | 0.6 | 123,966 | New | +$1.75M | 0.08 | |
| State Street | $915,197.00 | 0.31 | 64,724 | -80.4% | -$3.75M | <0.0001 | |
| Barclays | $754,000.00 | 0.26 | 53,258 | New | +$754,000.00 | <0.0001 | |
| Citigroup | $743,835.00 | 0.25 | 52,605 | New | +$743,835.00 | <0.01 | |
| Newtyn Management | $653,112.00 | 0.22 | 46,189 | -94.39% | -$10.99M | 0.14 | |
| Qube Research & Technologies | $588,493.00 | 0.2 | 41,619 | +5,704.6% | +$578,354.61 | <0.01 | |
| Northern Trust | $519,504.00 | 0.18 | 36,740 | -79.63% | -$2.03M | <0.0001 | |
| Marathon Trading Investment Management Llc | $400,728.00 | 0.14 | 28,340 | New | +$400,728.00 | 0.16 | |
| Squarepoint Ops LLC | $384,184.00 | 0.13 | 27,170 | -35.82% | -$214,419.07 | <0.01 | |
| Quinn Opportunity Partners Llc | $379,362.00 | 0.13 | 26,829 | -93.26% | -$5.25M | 0.05 | |
| Dimensional Fund Advisors | $375,315.00 | 0.13 | 26,543 | -85.93% | -$2.29M | <0.0001 | |
| Shay Capital Llc | $330,805.00 | 0.11 | 23,395 | New | +$330,805.00 | 0.1 | |
| Walleye Capital | $231,458.00 | 0.08 | 16,369 | New | +$231,458.00 | <0.01 | |
| Two Sigma Advisers LP | $228,644.00 | 0.08 | 16,170 | -96.5% | -$6.31M | <0.0001 | |
| Cantor Fitzgerald L P | $218,406.00 | 0.07 | 15,446 | -90.23% | -$2.02M | <0.01 | |
| Balyasny Asset Management Llc | $200,760.00 | 0.07 | 14,198 | New | +$200,760.00 | <0.01 | |
| Two Sigma | $167,446.00 | 0.06 | 11,842 | -97.35% | -$6.14M | <0.0001 | |
| Charles Schwab | $151,482.00 | 0.05 | 10,713 | -70.58% | -$363,398.43 | <0.0001 | |
| Group One Trading | $130,795.00 | 0.05 | 9,250 | -43.28% | -$99,785.98 | <0.01 | |
| Point72 Asia Singapore Pte Ltd | $131,168.00 | 0.05 | 9,276 | New | +$131,168.00 | 0.01 | |
| Cubist Systematic Strategies | $119,945.00 | 0.04 | 8,483 | New | +$119,945.00 | <0.01 | |
| Acadian Asset Management | $41,000.00 | 0.01 | 2,902 | -89.61% | -$353,670.92 | <0.0001 | |
| Macquarie Group | $37,000.00 | 0.01 | 2,586 | New | +$37,000.00 | <0.0001 | |
| Advisor Group Holdings Inc | $28,987.00 | 0.01 | 2,050 | -97.96% | -$1.39M | <0.0001 | |
| Tower Research Capital | $14,183.00 | 0.01 | 1,003 | +45.15% | +$4,411.86 | <0.0001 | |
| UBS | $13,179.00 | <0.01 | 932 | +14.36% | +$1,654.44 | <0.0001 |